On Thursday, Genetic Technologies Limited (ADR) (NASDAQ:GENE)’s shares inclined 6.19% to $3.09.
GENE offered 20.40% EPS for prior five years. The company has -268.60% return on equity value while its ROI ratio was -46.70%. The company has $23.42 million market capitalizations and the institutional ownership was 37.80%. Its price to book ratio was 2.18. Volatility of the stock was 24.39% for the week while for the month booked as 10.53%.
The mean estimate for the short term price target for Genetic Technologies Limited (ADR) (NASDAQ:GENE) stands at $12.50 according to 1 Analysts. The higher price target estimate for the stock has been calculated at $12.50 while the lower price target estimate is at $12.50.
Analysts mean recommendation for the stock is 3.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Genetic Technologies Limited is a molecular diagnostics company. The Company offers predictive testing and assessment tools to assist physicians manage women’s health.
Alere Inc (NYSE:ALR)’s shares dropped -9.34% to $42.43.
ALR has beta value of 1.66. The company has the market capitalization of $4.01 billion. Return on assets ratio of the company was 3.40% while its return on equity ratio was 15.80%. ATR value of company was 1.81 while stock volatility for week was 3.64% while for month was 2.99%. Debt to equity ratio of the company was -2.32 and its current ratio was 1.70.
The mean estimate for the short term price target for Alere Inc (NYSE:ALR) stands at $52.57 according to 7 Analysts. The higher price target estimate for the stock has been calculated at $60.00 while the lower price target estimate is at $39.00.
Analysts mean recommendation for the stock is 1.80. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Alere Inc. is a provider of health information through diagnostic tests. The Company operates through professional diagnostics, patient self-testing, consumer diagnostics and, corporate and other segments.
At the end of Thursday’s trade, Illumina, Inc. (NASDAQ:ILMN)‘s shares dipped -2.71% to $154.75.
ILMN has market value of $23.29 billion while its EPS was booked as $3.43 in the last 12 months. The stock has 146.40 million shares outstanding while 93.10% shares of the company were owned by institutional investors. In the profitability analysis, the company has gross profit margin of 71.20% while net profit margin was 23.80%. Beta value of the company was 0.70; beta is used to measure riskiness of the security.
The mean estimate for the short term price target for Illumina, Inc. (NASDAQ:ILMN) stands at $184.53 according to 20 Analysts. The higher price target estimate for the stock has been calculated at $240.00 while the lower price target estimate is at $134.00.
Analysts mean recommendation for the stock is 2.10. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
